Moderna Inc.
MRNA | NASDAQ
$172.94
+$18.90 (+12.27%)
At close: Sep 21, 2026, 4:00 PM ET
$169.25
-$3.69 (-2.13%)
Pre-market:
Sep 22, 2026, 8:18 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.94B | 3.2B | 6.85B | 18.88B | 17.74B | 803.4M |
Cost of Revenue | 868M | 1.46B | 4.69B | 5.42B | 2.62B | 39.18M |
Gross Profit | 1.08B | 1.74B | 2.16B | 13.46B | 15.12B | 764.21M |
Operating Income | -3.07B | -3.95B | -4.24B | 9.42B | 13.3B | -763.14M |
Interest Income | 314M | 425M | 421M | 200M | 18M | 24.72M |
Pretax Income | -2.77B | -3.61B | -3.94B | 9.58B | 13.29B | -744.51M |
Net Income | -2.82B | -3.56B | -4.71B | 8.36B | 12.2B | -747.06M |
Selling & General & Admin | 1.02B | 1.17B | 1.55B | 1.13B | 567M | 188.27M |
Research & Development | 3.13B | 4.54B | 4.85B | 3.3B | 1.99B | 1.37B |
Other Expenses | n/a | -37M | n/a | -388M | -735M | -31.25M |
Operating Expenses | 4.15B | 5.68B | 6.39B | 4.04B | 1.82B | 1.53B |
Interest Expense | 10M | 24M | 38M | 29M | 18M | 9.89M |
Selling & Marketing Expenses | n/a | 146M | 204M | 121M | n/a | n/a |
Cost & Expenses | 5.02B | 7.14B | 11.09B | 9.46B | 4.44B | 1.57B |
Income Tax Expense | 54M | -46M | 772M | 1.21B | 1.08B | 2.55M |
Shares Outstanding (Basic) | 389M | 384M | 382M | 394M | 403M | 381.33M |
Shares Outstanding (Diluted) | 389M | 384M | 382M | 416M | 431M | 381.33M |
EPS (Basic) | -7.26 | -9.27 | -12.34 | 21.26 | 30.31 | -1.96 |
EPS (Diluted) | -7.26 | -9.27 | -12.34 | 20.10 | 28.29 | -1.96 |
EBITDA | -2.55B | -3.39B | -3.28B | 9.95B | 13.54B | -703.38M |
EBIT | -2.77B | -3.58B | -3.9B | 9.6B | 13.3B | -734.63M |
Depreciation & Amortization | 215M | 189M | 621M | 348M | 232M | 31.25M |
Add to Watchlist
Select watchlists to add or remove MRNA